View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 12, 2021updated 12 Jul 2022 11:20am

AstraZeneca’s Farxiga falls short in Phase III Covid-19 trial

Results from a Phase III clinical trial to see if AstraZeneca’s (AZ’s) diabetes and heart failure drug Farxiga (dapagliflozin) could help treat high-risk patients hospitalised with Covid-19 have shown that the drug failed to make an impact.

By Kezia Parkins

Results from a Phase III clinical trial to see if AstraZeneca’s (AZ’s) diabetes and heart failure drug Farxiga (dapagliflozin) could help treat high-risk patients hospitalised with Covid-19 have shown that the drug failed to make an impact.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The DARE-19 trial found that giving Farxiga to treat patients hospitalised with Covid-19 who are at risk of developing serious complications, “did not achieve statistical significance” for the primary endpoints of reducing organ dysfunction and all-cause mortality, nor did it boost recovery.

The DARE-19 trial is part of AZ’s efforts to develop new treatments and re-purpose existing ones to prevent and treat Covid-19.

Farxiga is AZ’s first-in-class sodium-glucose co-transporter-2 (SGLT2) inhibitor.

The DARE-19 trial began a year ago at Saint Luke’s Mid America Heart Institute in the US, and was the first to test a drug in the SGLT2 inhibitor class for its potential to treat patients hospitalised with Covid-19 who also have risk factors for developing serious complications.

These complications include hypertension, Type 2 diabetes (T2D), atherosclerotic cardiovascular disease, heart failure and chronic kidney disease.

AstraZeneca’s reasoning for testing the drug is that patients with heart, kidney or metabolic illnesses such as diabetes are at increased risk of developing deadly complications such as organ failure and are more likely to die, and earlier studies of Farxiga have shown that the drug can protect these organs.

In the international, randomised, double-blind, placebo-controlled Phase III trial, Farxiga was given over a 30-day period to 1,250 Covid-19 patients with illnesses including high blood pressure, T2D, heart failure and chronic kidney disease in addition to standard care.

It’s not all bad news for Farxiga’s trial in Covid-19 patients. While the drug failed to make any meaningful impact on patient outcomes, it disproved concerns from some expert groups that had previously advised that SGLT2 inhibitors be discontinued in all patients hospitalised with Covid-19 due to an increased risk for diabetic ketoacidosis.

“DARE-19 provided important data on the potential benefits and risks of using SGLT2 inhibitors to treat hospitalised patients with Covid-19,” said DARE-19’s lead investigator Mikhail Kosiborod.

“While the trial did not achieve statistical significance, the findings are very interesting and valuable, and will inform future clinical science. Also, of importance, we learned that dapagliflozin’s well-established safety profile was consistent in DARE-19.”

AZ executive vice president for biopharmaceuticals R&D Mene Pangalos said: “Prior to the DARE-19 Phase III trial, there was little data on the use of SGLT2 inhibitors in hospitalised patients with Covid-19 and we have now helped to fill this knowledge gap. We look forward to the efficacy and safety data being presented in the coming weeks.”

The last few months have been a rollercoaster for AstraZeneca, with its Covid-19 vaccine being put under the spotlight and its use restricted by European and British drug regulators after confirming a potential link to rare blood clots.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena